Processa Pharmaceuticals (PCSA) Other Operating Expenses (2012 - 2020)
Processa Pharmaceuticals' (PCSA) quarterly Other Operating Expenses came in at $2.0 million in Q3 2020, up 260516.67% YoY from N/an in Q4 2019, and up 10483.14% on a QoQ basis from -$19262.0 in Q2 2020.
Processa Pharmaceuticals (PCSA) Other Operating Expenses (2012 - 2020) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 9 years of Other Operating Expenses data on file, last reported at $2.0 million in Q3 2020.
- Quarterly Other Operating Expenses rose 260516.67% year-over-year to $2.0 million in Q3 2020, while the trailing twelve-month figure through Jun 2021 was $2.0 million (up 10085.02% YoY) and the FY2016 annual result came in at -$25000.0, up 58.84% from the prior year.
- Other Operating Expenses rose to $2.0 million in Q3 2020, from -$19262.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $2.0 million in Q3 2020 to a low of -$63322.0 in Q3 2016.
- A 5-year average of $141230.4 and a median of -$2704.0 in 2019 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2018 — Other Operating Expenses plunged 3045.1% — and 2020, when it soared 260516.67%.
- Tracing PCSA's Other Operating Expenses over 5 years: stood at $131907.0 in 2016, then slumped by 99.03% to $1284.0 in 2017, then plunged by 245.33% to -$1866.0 in 2018, then soared by 58.84% to -$768.0 in 2019, then soared by 260516.67% to $2.0 million in 2020.
- The last three Other Operating Expenses figures came in at $2.0 million (Q3 2020), -$19262.0 (Q2 2020), and -$768.0 (Q3 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 2.00 Mn |
| Jun 30, 2020 | -19,262.00 |
| Sep 30, 2019 | -768.00 |
| Jun 30, 2019 | -2,704.00 |
| Sep 30, 2018 | -1,866.00 |
| Jun 30, 2018 | -55,633.00 |
| Sep 30, 2017 | 1,284.00 |
| Jun 30, 2017 | 1,889.00 |
| Mar 31, 2017 | -61,945.00 |
| Dec 31, 2016 | 131,907.00 |
| Sep 30, 2016 | -63,322.00 |
| Jun 30, 2016 | -37,479.00 |
| Mar 31, 2016 | -56,106.00 |
| Dec 31, 2015 | -60,743.00 |
| Sep 30, 2015 | -97,478.00 |
| Jun 30, 2015 | -3,753.00 |
| Mar 31, 2015 | -34,019.00 |
| Dec 31, 2014 | -12,057.00 |
| Sep 30, 2014 | -130,134.00 |
| Jun 30, 2014 | -112,933.00 |